Completed PHASE1 INTERVENTIONAL 1-arm NCT02253264

A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients

A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement

Sponsor: Johns Hopkins University

Conditions Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Interventions Rituximab

Updated 7 times since 2017 Last updated: Aug 29, 2017 Started: Nov 30, 2014 Primary completion: Aug 31, 2017 Completion: Aug 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis and is currently completed. Johns Hopkins University leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Sep 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 2 earlier versions

Feb 2017 — Sep 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johns Hopkins University

Data source: Johns Hopkins University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States